These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 649995)

  • 1. Cefamandole in treatment of peritonitis.
    Stone HH; Guest BS; Geheber CE; Kolb LD
    J Infect Dis; 1978 May; 137 Suppl():S103-S109. PubMed ID: 649995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of obstetric and gynecologic infections with cefamandole.
    Cunningham FG; Gilstrap LC; Kappus SS
    Am J Obstet Gynecol; 1979 Mar; 133(6):602-10. PubMed ID: 426015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with cefamandole for treatment of serious bone and joint infections.
    Levine LR; McCain E
    J Infect Dis; 1978 May; 137 Suppl():S119-S124. PubMed ID: 649996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial peritonitis. Protecting the high-risk patient.
    Jones LM; Miller S
    Am Surg; 1984 Jul; 50(7):358-61. PubMed ID: 6378000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of serious infections with cefamandole.
    Parry MF; Goldberger MJ; Neu HC
    Infection; 1978; 6(5):236-40. PubMed ID: 365776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefamandole therapy of endomyometritis following cesarean section.
    Gibbs RS; Huff RW
    Am J Obstet Gynecol; 1980 Jan; 136(1):32-7. PubMed ID: 7352484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cefamandole therapy in obstetric and gynecologic infections.
    Gall SA; Hill GB
    Am J Obstet Gynecol; 1980 Aug; 137(8):914-22. PubMed ID: 7405988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.
    Perkins RL; Fass RJ; Warner JF; Prior RB; File TM; Tight RR; Gardner WG; Ruiz DE; Slama TG
    J Infect Dis; 1978 May; 137 Suppl():S110-S118. PubMed ID: 418126
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of serious anaerobic infections.
    Greenberg RN; Scalcini MC; Sanders CV; Lewis AC
    Scand J Infect Dis Suppl; 1980; suppl 25():84-8. PubMed ID: 7010541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefamandole therapy in anaerobic infections.
    Greenberg RN; Scalcini MC; Sanders CV; Lewis AC
    Antimicrob Agents Chemother; 1979 Mar; 15(3):337-41. PubMed ID: 380458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory investigation of cefamandole therapy of infections in infants and children.
    Azimi PH
    J Infect Dis; 1978 May; 137 Suppl():S155-S160. PubMed ID: 349094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefamandole for treatment of obstetrical and gynecological infections.
    Cunningham FG; Gilstrap LC; Kappus SS
    Scand J Infect Dis Suppl; 1980; suppl 25():75-82. PubMed ID: 7010540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefamandole--effectiveness against anaerobes: supplementary remarks.
    Levine LR
    Scand J Infect Dis Suppl; 1980; suppl 25():94-5. PubMed ID: 7010543
    [No Abstract]   [Full Text] [Related]  

  • 14. Cefamandole nafate: an evaluation of antibacterial activity, serum levels, clinical effect, and incidence of side reactions in 58 patients.
    Ekwall E; Holmgren EB; Lundbergh P; Svanbom M; Tunevall G
    Scand J Infect Dis; 1979; 11(2):135-9. PubMed ID: 462128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefamandole and cefazolin in the therapy of complicated urinary tract infections.
    Hoyme U; Madsen PO
    J Infect Dis; 1978 May; 137 Suppl():S100-S102. PubMed ID: 349091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbenicillin plus cefamandole in the treatment of infections in patients with cancer.
    Bodey GP; Ketchel S; Rodriguez V
    J Infect Dis; 1978 May; 137 Suppl():S139-S143. PubMed ID: 649998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of cefamandole in the treatment of soft tissue and skeletal infections.
    LeFrock JL; Paparone P; Kowalsky SF; Schell RF; Jacobs RL; Wirth CR; Tillotson JR
    Drug Intell Clin Pharm; 1981 Dec; 15(12):951-7. PubMed ID: 7338190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to cefamandole: a collaborative study of emerging clinical problems.
    Sanders CC; Moellering RC; Martin RR; Perkins RL; Strike DG; Gootz TD; Sanders WE
    J Infect Dis; 1982 Jan; 145(1):118-25. PubMed ID: 6274965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of cefamandole nafate.
    Rosett W; Hodges GR; Harms J; Gerjarusak P; Dworzack D; Hinthorn DR; Liu C
    Am J Med Sci; 1977; 274(2):153-61. PubMed ID: 341707
    [No Abstract]   [Full Text] [Related]  

  • 20. Cefamandole in the treatment of soft tissue infections.
    Ramírez-Ronda CH; Quiñones-Soto R; Lugo-Velázquez A; Bermúdez RH
    Chemotherapy; 1982; 28(3):224-8. PubMed ID: 7094663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.